Clinical trials: Motor Neuron Disorder
Amyotrophic Lateral Sclerosis
Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)
This study will assess the effect of cimetidine on the pharmacokinetics (PK) of dexpramipexole in healthy volunteer and evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine.
- Trial name
- NCT01536249
- Testing
- Dexpramipexole, Cimetidine plus Dexpramipexole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis, Neuromuscular Diseases
Emotion Processing Among Patients With ALS
The goal of this observational study is to learn about the emotional perception in people with ALS disease compared to people with other neuromuscular disease and healthy controls.
- Conditions
- Amyotrophic Lateral Sclerosis, Neuromuscular Diseases, ALS, Motor Neuron Disease
- Trial name
- NCT06566651
- Testing
- Emotion Discrimination Task (EDT)
- Where
- 2 sites in Denmark
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Amyotrophic Lateral Sclerosis (ALS)
PET Imaging in ALS Patients
This is a pilot study to evaluate a potential imaging biomarker for aiding diagnosis and monitoring progression of ALS, based on a well established basic science pathway, published human autopsy data, preliminary data in ALS…
- Trial name
- NCT02236897
- Testing
- PET Scanning
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis (ALS)
Identification of Early Markers for ALS
Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available.
- Trial name
- PremodiALS (NCT07213440)
- Testing
- lumbar puncture
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Spinal Muscular Atrophy Type 3, Mitochondrial Myopathy
Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
This proposal will focus on (1) estimating oxidative capacity of specific muscle groups during exercise using near infrared spectroscopy and (2) describing body composition to better understand exercise capacity and mitochondrial…
- Trial name
- NCT02895789
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Columbia University
ALS (Amyotrophic Lateral Sclerosis)
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality.
- Trial name
- NCT07321860
- Testing
- Galunisertib + Nerandomilast Combination
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gipfel Life Sciences GmbH
Parkinson's Disease (PD), Alzheimer's Disease (AD)
Quantification of Hsp90 in the Human Brain
This study tests the radiolabeled molecule ("tracer"), [¹¹C]HSP990, using positron emission tomography (PET) imaging to assess whether it can be used to measure levels of Heat Shock Protein 90 (Hsp90).
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- NCT07380204
- Testing
- [11C]HSP990 PET dosimetry, [11C]HSP990 PET test-retest, [11C]HSP990 simplified scan protocol
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Spinal Muscular Atrophy
Motor Unit Number Estimation (MUNE) in Adults With Spinal Muscular Atrophy (SMA)
The primary objective of this research protocol is to study and follow the course of motor neuron loss in individuals with spinal muscular atrophy (SMA) using the electrophysiological technique of motor unit number estimation…
- Trial name
- NCT04139343
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Spinal Muscular Atrophy, Neonatal Hyperbilirubinemia
Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.
In this, here we want to present a new method for analysis variation in gene copy number for patients and carriers of SMA. This is a relative quantitation method and, therefore, relies on the inclusion of one or more internal…
- Conditions
- Spinal Muscular Atrophy, Neonatal Hyperbilirubinemia, Colon Cancer
- Trial name
- NCT00154960
- Where
- Taiwan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Amyotrophic Lateral Sclerosis
Reinnervation and Neuromuscular Transmission in ALS
The aim of this study is to describe the changes in the neuromuscular connection in patients with amyotrophic lateral sclerosis (ALS). The study consist of three substudies that have the following main hypothesis: 1.
- Trial name
- RANTAL (NCT06219759)
- Testing
- Observational study
- Where
- Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Imaging Biomarkers in ALS
The purpose of the study is to determine if we are able to find one or more biomarkers of Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS) using magnetic resonance imaging (MRI) scans at different levels, 3…
- Trial name
- NCT02567136
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease
Brief summary template The goal of this trial is to test the feasibility and efficacy of the Mediterranean-DASH Intervention for Neurodegenerative Delay (the MIND diet) in people living with amyotrophic lateral sclerosis (ALS)…
- Trial name
- Meals (NCT07625605)
- Testing
- The MIND diet
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Tennessee, Knoxville
Amyotrophic Lateral Sclerosis
PREVENT ALL ALS Study
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control…
- Trial name
- NCT06581861
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Amyotrophic Lateral Sclerosis, Bulbar Disease
Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis
PET imaging of activated microglia offers a tool of investigation of a range of brain diseases where neuroinflammation is a component. Amyotrophic lateral sclerosis is the most frequent motoneuronal disease in adult.
- Conditions
- Amyotrophic Lateral Sclerosis, Bulbar Disease, Spinal Disease
- Trial name
- NCT00563537
- Testing
- 18F-X PET SCAN
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis
DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease
In response to oxidative stress, cells activate the Nrf-2 pathway, which induces translation of its target genes and corresponding proteins involved in the antioxidant response.
- Trial name
- DIAGALS (NCT06230562)
- Testing
- Blood sample
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Neuromuscular Diseases
Muscle Oxygenation in Effort in Neuromuscular Diseases
Previous studies showed modifications of muscle oxygenation parameters in muscular dystrophies du to an impairment or an absence of dystrophin.
- Trial name
- OXYNEMU (NCT02789059)
- Testing
- muscle oxygenation
- Where
- 3 sites in France
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
This study is evaluating the use of two painless, non-invasive technologies in the assessment of muscle health over time in both healthy volunteers and patients who have diseases that affect the nervous system.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Myopathies, Stroke
- Trial name
- QUESST (NCT02118805)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative…
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Primary Lateral Sclerosis, Nervous System Diseases
- Trial name
- BIO_ALS-01 (NCT00677768)
- Testing
- No intervention
- Where
- 30 sites in United States, Canada
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders
The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish…
- Trial name
- NCT05474235
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis, ALS
MRI Biomarkers in ALS
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Motor Neuron Diseases
- Trial name
- NCT02405182
- Testing
- Magnetic Resonance Imaging
- Where
- 6 sites in Canada
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of Alberta